Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKY-2519
- Development stage
- Phase 1
- Lead developer
- Aktis Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
AKY-2519 is a miniprotein radioconjugate (MRC) being developed by Aktis Oncology for the treatment of various solid tumors, including prostate and lung cancers. It targets B7-H3 (CD276), a protein frequently overexpressed in many solid malignancies. The drug utilizes actinium-225 (225Ac), an alpha-emitting radioisotope, to deliver high-energy, short-range radiation directly to tumor cells, causing lethal double-strand DNA breaks. The miniprotein scaffold is designed to be smaller than traditional antibodies, facilitating rapid tumor penetration and internalization while maintaining high affinity and prolonged retention, potentially improving the therapeutic index compared to larger radiopharmaceuticals.
- Other names
- Ac-AKY-2519Ac-AKY2519Ac-AKY 2519
02
Targets
B7-H3
Beyond the preview
Go deeper on AKY-2519.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKY-2519.